Literature DB >> 18639284

Identification of novel epigenetic markers for clear cell renal cell carcinoma.

Gul S Dalgin1, Michele Drever, Tara Williams, Thomas King, Charles DeLisi, Louis S Liou.   

Abstract

PURPOSE: We identified significantly hypermethylated genes in clear cell renal cell carcinoma.
MATERIALS AND METHODS: We previously identified a set of under expressed genes in renal cell carcinoma tissue through transcriptional profiling and a robust computational screen. We selected 19 of these genes for hypermethylation analysis using a rigorous search for the best candidate regions, considering CpG islands and transcription factor binding sites. The genes were analyzed for hypermethylation in the DNA of 38 matched clear cell renal cell carcinoma and normal samples using matrix assisted laser desorption ionization time-of-flight mass spectrometry. The significance of hypermethylation was assessed using 3 statistical tests. We validated the down-regulation of significantly hypermethylated genes at the RNA and protein levels in a separate set of patients using reverse transcriptase-polymerase chain reaction, immunohistochemistry and Western blots.
RESULTS: We found 7 significantly hypermethylated regions from 6 down-regulated genes, including SFRP1, which was previously shown to be hypermethylated in renal cell carcinoma and other cancer types.
CONCLUSIONS: To our knowledge we report for the first time that another 5 genes (SCNN1B, SYT6, DACH1, and the tumor suppressors TFAP2A and MT1G) are hypermethylated in renal cell carcinoma. Robust computational screens and the high throughput methylation assay resulted in an enriched set of novel genes that are epigenetically altered in clear cell renal cell carcinoma. Overall the detection of hypermethylation in these highly down-regulated genes suggests that assaying for their methylation using cells from urine or blood could provide the basis for a viable diagnostic test.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18639284     DOI: 10.1016/j.juro.2008.04.137

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  23 in total

Review 1.  Epigenetics of kidney cancer and bladder cancer.

Authors:  Amanda M Hoffman; Paul Cairns
Journal:  Epigenomics       Date:  2011-02       Impact factor: 4.778

Review 2.  Breaking through a plateau in renal cell carcinoma therapeutics: development and incorporation of biomarkers.

Authors:  Sumanta Kumar Pal; Marcin Kortylewski; Hua Yu; Robert A Figlin
Journal:  Mol Cancer Ther       Date:  2010-11-15       Impact factor: 6.261

3.  Genome-wide methylation profiling of ADPKD identified epigenetically regulated genes associated with renal cyst development.

Authors:  Yu Mi Woo; Jae-Bum Bae; Yeon-Hee Oh; Young-Gun Lee; Min Joo Lee; Eun Young Park; Jung-Kyoon Choi; Sunyoung Lee; Yubin Shin; Jaemyun Lyu; Hye-Yoon Jung; Yeon-Su Lee; Young-Hwan Hwang; Young-Joon Kim; Jong Hoon Park
Journal:  Hum Genet       Date:  2013-10-16       Impact factor: 4.132

4.  A genome-wide screen identifies frequently methylated genes in haematological and epithelial cancers.

Authors:  Thomas Dunwell; Luke Hesson; Tibor A Rauch; Lihui Wang; Richard E Clark; Ashraf Dallol; Dean Gentle; Daniel Catchpoole; Eamonn R Maher; Gerd P Pfeifer; Farida Latif
Journal:  Mol Cancer       Date:  2010-02-25       Impact factor: 27.401

5.  Effects of parathyroid hormone-related protein and macrophage inflammatory protein-1α in Jurkat T-cells on tumor formation in vivo and expression of apoptosis regulatory genes in vitro.

Authors:  Sherry T Shu; Wessel P Dirksen; Lisa G Lanigan; Chelsea K Martin; Nanda K Thudi; Jillian L Werbeck; Soledad A Fernandez; Blake E Hildreth; Thomas J Rosol
Journal:  Leuk Lymphoma       Date:  2012-01-03

6.  Polycomb group genes are targets of aberrant DNA methylation in renal cell carcinoma.

Authors:  Michele Avissar-Whiting; Devin C Koestler; E Andres Houseman; Brock C Christensen; Karl T Kelsey; Carmen J Marsit
Journal:  Epigenetics       Date:  2011-06-01       Impact factor: 4.528

Review 7.  Ependymoma in children: molecular considerations and therapeutic insights.

Authors:  J-H Kim; Y Huang; A S Griffin; P Rajappa; J P Greenfield
Journal:  Clin Transl Oncol       Date:  2013-04-25       Impact factor: 3.405

8.  Portrait of ependymoma recurrence in children: biomarkers of tumor progression identified by dual-color microarray-based gene expression analysis.

Authors:  Matthieu Peyre; Frédéric Commo; Carmela Dantas-Barbosa; Felipe Andreiuolo; Stéphanie Puget; Ludovic Lacroix; Françoise Drusch; Véronique Scott; Pascale Varlet; Audrey Mauguen; Philippe Dessen; Vladimir Lazar; Gilles Vassal; Jacques Grill
Journal:  PLoS One       Date:  2010-09-24       Impact factor: 3.240

9.  TFAP2E hypermethylation was associated with survival advantage in patients with colorectal cancer.

Authors:  Zuo-Ming Zhang; Yibaina Wang; Rong Huang; Yu-Peng Liu; Xia Li; Fu-Lan Hu; Lin Zhu; Fan Wang; Bin-Bin Cui; Xin-Shu Dong; Ya-Shuang Zhao
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-06       Impact factor: 4.553

Review 10.  From bench to bedside: current and future applications of molecular profiling in renal cell carcinoma.

Authors:  Androu Arsanious; Georg A Bjarnason; George M Yousef
Journal:  Mol Cancer       Date:  2009-03-17       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.